EXPERIENCE IN THE USE OF MUCOREGULATING DRUGS IN THE COMPLEX THERAPY OF RHINOSINUSITIS

Abstract

The objective of this clinical trial (CRS-01) was to assess the efficacy, safety and tolerability of the herbal medicinal product BNO 1016 (Sinupret extract) in patients with chronic rhinosinusitis (CRS). In total, we observed 74 patients with acute and chronic rhinosinusitis, who received Sinupret Extract as part of complex therapy. The control group consisted of 25 patients receiving antibiotic therapy, but without secretolytics. Sinupret was prescribed according to the scheme: 1 tablet 3 times a day, the duration of treatment averaged 14 days. All patients underwent measurements of mucociliary transport before treatment, on the 7th day and on the 14th day of treatment, which allowed us to evaluate the comparative effectiveness of the treatment.

As a result of our study, we found a significant acceleration of mucociliary transport. This was especially noted in the first week of treatment. In addition, when analyzing the dynamics of the main rhinoscopic indicators among patients who received Sinupret Extract, a faster decrease in symptoms such as edema and hyperemia of the mucous membrane was noted, and the amount of pathological secretions also decreased. In summary, the present study has demonstrated that Sinupret extract can be recommended for the treatment of patients with chronic rhinosinusitis. Future trials are needed to substantiate the treatment effect. Selection of subgroups should be done with care e.g. maybe also considering new findings on inflammation endotypes via biomarker analysis. This work shows, that the disease should persist long enough with a certain degree of severeness and patients should be diagnosed and treated by a specialist in otorhinolaryngology.